AVITA MEDICAL WKN: A0Q40S ISIN: AU000000AVH4 Kürzel: AVMXF Forum: Aktien Thema: Hauptdiskussion
2,38 EUR
-1,65 %-0,04
29. Nov, 08:33:13 Uhr,
L&S Exchange
Kommentare 608
S
Streuselinho,
14.11.2019 10:05 Uhr
0
Erst bei 0,3 wieder :)
M
Magelan,
14.11.2019 6:11 Uhr
0
Bei dem Wert werde ich heute nachlegen
Li27,
13.11.2019 11:41 Uhr
0
da ich letzte Woche verdoppelt habe bin ich jetzt etwas im Minus... aber die Richtung auf lange Sicht ist entscheidend.
S
Streuselinho,
13.11.2019 8:53 Uhr
0
Es ist und bleibt ein volatiler pennystock.
M
Magelan,
13.11.2019 7:16 Uhr
0
Puhh was ist den los, habe was anderes erwartet
odi001,
13.11.2019 4:31 Uhr
0
ASX/News Release
AVITA Medical Announces Institutional Placement of A$120.0 Million
to Support Commercial Growth and Pipeline Development
Valencia, Calif., USA, and Melbourne, Australia, 13 November 2019 — AVITA Medical (ASX: AVH, NASDAQ:
RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical
needs in therapeutic skin restoration, announced today an institutional placement of A$120.0 million
(Institutional Placement) to fund pipeline development of new indications, including optimizing support for
clinical trials and development projects, as well as the Company’s continued U.S. commercial growth
strategy.
The Institutional Placement was managed by Bell Potter as sole lead manager. Cowen served as financial
advisor to the Company in connection with the Institutional Placement. Lake Street Capital Markets also
acted as a financial advisor to Avita Medical. The Company has received commitments for A$120.0 million at
an issue price of A$0.59 per fully paid ordinary share, representing a 7.2 percent discount to the 30-day
VWAP, and a 14.5 percent discount to the last closing price on 8 November 2019. The new AVITA shares to
be issued under the Institutional Placement will rank equally with existing AVITA shares on issue. The
Institutional Placement will occur in a single tranche, and issue 203,389,831 shares to international and
Australian sophisticated investors under its 15 percent placement capacity (under ASX Listing Rule 7.1).
“We are grateful for the confidence and conviction of the investors who have joined us in our mission to
transform burn care with our revolutionary RECELL® System and to promptly execute on our pipeline of
add-on indications,” said Dr. Mike Perry, Chief Executive Officer. “This financing reflects our shared
excitement for, and strong confidence in, AVITA Medical’s myriad near-term growth opportunities. These
include trauma/soft tissue reconstruction, vitiligo, our next generation RECELL device to facilitate use of the
RECELL System in the outpatient setting, and pediatric scald wounds, as well as efforts to enable research
programs to support the advancement and extension of our existing intellectual property. Through diligent
and focused execution on our highly de-risked pipeline of new indications, we have the opportunity to
access the full potential of our innovative regenerative medicine platform to advance patient care that
addresses unmet medical needs, while aggressively growing our top *** revenues and ultimately building a
robust self-sustaining business.”
Accelerating pipeline development
The funds from the Institutional Placement will enable AVITA Medical to fast-track progression of clinical
development programs and to accelerate its broader commercialization strategy. Key initiatives include:
• Initiating U.S. pivotal trials to establish the safety and efficacy of the RECELL System in soft tissue
reconstruction and traumatic wounds, as well as early intervention in the treatment of pediatric
scald wounds
• Further development and submission to the FDA of a next generation RECELL System to facilitate
access to the large outpatient market
• Pilot studies with the RECELL System for the treatment of vitiligo, and subsequent rapid
advancement into a pivotal clinical trial to secureadva this indication in the U.S.
For personal use only
D
DividendenJoe,
12.11.2019 16:23 Uhr
0
Ok top, danke 👍
M
Magelan,
12.11.2019 14:26 Uhr
0
eVo99 => weil Avita ins ASX200 rauf rutscht
Willilex64,
12.11.2019 12:43 Uhr
0
Danke
D
DividendenJoe,
12.11.2019 12:36 Uhr
0
Warum?
odi001,
12.11.2019 11:55 Uhr
0
Vom Handel bis 14. 11 ausgesetzt
Willilex64,
12.11.2019 9:47 Uhr
0
Keine Bewegung seit Freitag?
odi001,
12.11.2019 6:23 Uhr
0
https://***.com.au/threads/powerful-cocktail.5066983/page-8?post_id=41379894
h.o.t.c.o.p.p.e.r
odi001,
11.11.2019 12:35 Uhr
0
https://www.afr.com/street-talk/avita-medical-raising-100-million-20191111-p539e7
Li27,
11.11.2019 9:08 Uhr
0
🚀🚀🚀
odi001,
11.11.2019 7:17 Uhr
0
h.o.t.c.o.p.p.e.r
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | ATOS Hauptdiskussion | +4,63 % | |
2 | Tonner Drones startet nach Vertrag mit Ukraine | +12,90 % | |
3 | TUI Hauptforum | -0,35 % | |
4 | Trading- und Aktien-Chat | ||
5 | Spineway Act Hauptdiskussion | +18,72 % | |
6 | MicroStrategy | +4,77 % | |
7 | EVOTEC Hauptdiskussion | +0,06 % | |
8 | CYTOMX THERAPEUTICS INC. Hauptdiskussion | -0,57 % | |
9 | Europlasma Hauptdiskussion | +15,38 % | |
10 | Norse Atlantic | ±0,00 % | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | ATOS Hauptdiskussion | +0,53 % | |
2 | Tonner Drones startet nach Vertrag mit Ukraine | +12,90 % | |
3 | TUI Hauptforum | -0,33 % | |
4 | Spineway Act Hauptdiskussion | +18,72 % | |
5 | MicroStrategy | +1,60 % | |
6 | EVOTEC Hauptdiskussion | +0,06 % | |
7 | Europlasma Hauptdiskussion | +15,38 % | |
8 | CYTOMX THERAPEUTICS INC. Hauptdiskussion | -0,57 % | |
9 | Norse Atlantic | ±0,00 % | |
10 | OCEAN POWER Hauptdiskussion | +2,45 % | Alle Diskussionen |